Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization

Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines

(2013) I. Savelieva et al.   EUROPACE

Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation

(2013) Diego Conde et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel

(2012) Alexander Burashnikov et al.   Circulation-Arrhythmia and Electrophysiology

Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial

(2012) A. J. Camm et al.   EUROPACE

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPACE

A Randomized, Placebo-Controlled Study of Vernakalant (Oral) for the Prevention of Atrial Fibrillation Recurrence After Cardioversion

(2011) Christian Torp-Pedersen et al.   Circulation-Arrhythmia and Electrophysiology

A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure

(2011) Gerrit Frommeyer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization

(2011) Peter Milberg et al.   HEART RHYTHM

Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations

(2011) Serge Sicouri et al.   HEART RHYTHM

Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease

(2011) Christian Torp-Pedersen et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation

(2011) A. John Camm et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ranolazine Reduces Ventricular Tachycardia Burden and ICD Shocks in Patients with Drug-Refractory ICD Shocks

(2011) T. JARED BUNCH et al.   PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY

Vernakalant Hydrochloride: A NovelAtrial-selective Agent for the Cardioversionof Recent-onset Atrial Fibrillation in the Emergency Department

(2010) Ian G. Stiell et al.   ACADEMIC EMERGENCY MEDICINE

A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm

(2010) Ian G. Stiell et al.   AMERICAN HEART JOURNAL

Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial Fibrillation

(2010) Craig M. Pratt et al.   AMERICAN JOURNAL OF CARDIOLOGY

Late Na+Current Inhibition by Ranolazine Reduces Torsades de Pointes in the Chronic Atrioventricular Block Dog Model

(2010) Gudrun Antoons et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion

(2009) Arvinder K. Dhalla et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery

(2009) Peter R. Kowey et al.   Circulation-Arrhythmia and Electrophysiology

Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation

(2008) Denis Roy et al.   CIRCULATION

Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations

(2008) Serge Sicouri et al.   HEART RHYTHM

Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3

(2008) Peter Milberg et al.   HEART RHYTHM